Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19408108 | 0.76 | MEN1 (0.32) | MEN1KMT2AL3MBTL1HTR2AHTR2C | |
| SCHEMBL10840512 | 0.71 | HTR2C (0.45) | MEN1KMT2AL3MBTL1HTR2AHTR2C | |
| SCHEMBL17513184 | 0.68 | MEN1 (0.41) | MEN1KMT2AL3MBTL1HTR2AHTR2C | |
| SCHEMBL17513185 | 0.68 | MEN1 (0.41) | MEN1KMT2AL3MBTL1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL19378062 | 0.67 | MEN1 (0.40) | MEN1KMT2AL3MBTL1HTR2AHTR2C | |
| SCHEMBL19701831 | 0.59 | HTR2C (0.46) | HTR2AHTR2CHTR2BHTR1ASLC6A2 | |
| SCHEMBL19377859 | 0.57 | MEN1 (0.50) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL23846917 | 0.57 | — | — | |
| SCHEMBL19703083 | 0.56 | HTR2C (0.45) | HTR2AHTR2CHTR2BHTR1ASLC6A2 | |
| SCHEMBL20932957 | 0.55 | MAP3K14 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | MEN1 2418/4885KMT2A 1195/4885L3MBTL1 232/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | MEN1 2418/4885KMT2A 1195/4885L3MBTL1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.